|
Jul 3
|
Gilead Sciences (GILD) Announces that US FDA Approves Yeztugo®as pre-exposure prophylaxis (PrEP)
|
|
Jul 1
|
Chronic Hepatitis B Market Analysis and Forecast, 2025-2035 | Diagnostic Advances, Innovative Therapies, and Rising Awareness Bolster Growth
|
|
Jun 30
|
Assembly Biosciences Says First Participant Dosed in Phase 1b Study of HSV Drug ABI-1179
|
|
Jun 30
|
Gilead extends gains after Supreme Court upheld an Obamacare provision
|
|
Jun 30
|
This firm represents one of investing’s toughest moral debates
|
|
Jun 28
|
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer
|
|
Jun 27
|
Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know
|
|
Jun 27
|
Gilead Rises After Supreme Court Says Insurers Must Cover HIV Prevention Drugs
|
|
Jun 27
|
Kymera’s partnerships with Sanofi and Gilead drive value
|
|
Jun 27
|
Debut Named to TIME's List of the TIME100 Most Influential Companies 2025
|
|
Jun 26
|
Northwell Health named to TIME100 Most Influential Companies 2025 list
|
|
Jun 26
|
Kymera weakness a buying opportunity, says Stifel
|
|
Jun 26
|
Morning Movers: General Mills dips following fourth quarter report
|
|
Jun 26
|
KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update
|
|
Jun 25
|
Gilead Sciences (GILD) Stock Moves -1.18%: What You Should Know
|
|
Jun 25
|
Alger Russell Innovation Index Updates for Second Quarter 2025
|
|
Jun 25
|
Gilead Sciences (NasdaqGS:GILD) Partners With Kymera In US$750 Million Cancer Treatment Deal
|
|
Jun 25
|
FDA approves Gilead’s twice-yearly injectable Yeztugo for PrEP
|
|
Jun 25
|
Kymera adds Gilead as research partner, while advancing new candidate with Sanofi
|
|
Jun 25
|
Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B
|